Pediatric extended-release oral formulations: A U.S. market landscape analysis

Extended-release (ER) oral formulations provide therapeutic and practical benefits for pediatric patients by minimizing fluctuations in systemic exposure, reducing dosing frequency, and improving adherence. However, few reviews of ER formulations have focused specifically on the pediatric population. Accordingly, this review has two objectives. The first objective is to characterize the current U.S. market landscape of pediatric ER oral drug products using the U.S. Food and Drug Administration (FDA) Pediatric Labeling Changes database (1998-2023). The second objective is to evaluate the extent to which existing products address pediatric needs and to identify opportunities for future development based on the findings of this analysis. In the current U.S. market, 42 out of 266 pediatric-labeled oral prescription drugs are ER products. These products are concentrated in attention-deficit/hyperactivity disorder and seizure indications, and most are labeled for children 6 years of age and older. Conventional tablets and multiparticulate capsules are the predominant dosage forms, whereas suspensions, orally disintegrating tablets, and chewable tablets are less commonly represented. Four principal technology platforms are used: matrix systems, ion-exchange resins, functional coatings, and osmotic pumps, often in combination, to balance child-appropriate administration with robust release performance. The analysis highlights several opportunities for future development. Expanding ER development into additional chronic pediatric conditions, addressing the lack of options for children younger than 6 years of age, and strengthening pre-competitive knowledge sharing on formulation platforms and technologies represent the key priorities for broadening the availability of safe, effective, and child-friendly ER medicines.